Variation in seizure risk increases from antiseizure medication withdrawal among patients with well‐controlled epilepsy: A pooled analysis
Epilepsia Open · 2024-02 · 9 (1) · 333-344
DOI: 10.1002/epi4.12880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 16.12.2023. Verfasst von Samuel W Terman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Seizures, Epilepsy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Objective
Guidelines suggest considering antiseizure medication (ASM) discontinuation in seizure‐free patients with epilepsy. Past work has poorly explored how discontinuation effects vary between patients. We evaluated (1) what factors modify the influence of discontinuation on seizure risk; and (2) the range of seizure risk increase due to discontinuation across low‐ versus high‐risk patients.
Methods
We pooled three datasets including seizure‐free patients who did and did not discontinue ASMs. We conducted time‐to‐first‐seizure analyses. First, we evaluated what individual patient factors modified the relative effect of ASM discontinuation on seizure risk via interaction terms. Then, we assessed the distribution of 2‐year risk increase as predicted by our adjusted logistic regressions.
Results
We included 1626 patients, of whom 678 (42%) planned to discontinue all ASMs. The mean predicted 2‐year seizure risk was 43% [95% confidence interval (CI) 39%–46%] for discontinuation versus 21% (95% CI 19%–24%) for continuation. The mean 2‐year absolute seizure risk increase was 21% (95% CI 18%–26%). No individual interaction term was significant after correcting for multiple comparisons. The median [interquartile range (IQR)] risk increase across patients was 19% (IQR 14%–24%; range 7%–37%). Results were unchanged when restricting analyses to only the two RCTs. Significance No single patient factor significantly modified the influence of discontinuation on seizure risk, although we captured how absolute risk increases change for patients that are at low versus high risk. Patients should likely continue ASMs if even a 7% 2‐year increase in the chance of any more seizures would be too much and should likely discontinue ASMs if even a 37% risk increase would be too little. In between these extremes, individualized risk calculation and a careful understanding of patient preferences are critical. Future work will further develop a two‐armed individualized seizure risk calculator and contextualize seizure risk thresholds below which to consider discontinuation. Plain Language Summary Understanding how much antiseizure medications (ASMs) decrease seizure risk is an important part of determining which patients with epilepsy should be treated, especially for patients who have not had a seizure in a while. We found that there was a wide range in the amount that ASM discontinuation increases seizure risk—between 7% and 37%. We found that no single patient factor modified that amount. Understanding what a patient's seizure risk might be if they discontinued versus continued ASM treatment is critical to making informed decisions about whether the benefit of treatment outweighs the downsides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Child Neurology, UMC Utrecht Brain Center, Wilhelmina Children's Hospital, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.
- Department of Neurology, University of California San Francisco, San Fransisco, California, USA.
- University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Neurology, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Samuel W Terman, Geertruida Slinger, Willem M Otte
Förderung
- NIA NIH HHS
- NIH HHS
- NINDS NIH HHS
- NCATS NIH HHS
- Michigan Institute for Clinical and Health Research
- National Institute on Aging
- National Institutes of Health
- NIH Clinical Center
Zitieren
APA
Terman, S. W., Slinger, G., Koek, A., Skvarce, J., Springer, M. V., Ziobro, J. M., Burke, J. F., Otte, W. M., Thijs, R. D., Lossius, M. I., Marson, A. G., Bonnett, L. J., & Braun, K. P. J. (2024). Variation in seizure risk increases from antiseizure medication withdrawal among patients with well‐controlled epilepsy: A pooled analysis. Epilepsia Open, 9(1), 333-344. https://doi.org/10.1002/epi4.12880
Vancouver
Terman SW, Slinger G, Koek A, Skvarce J, Springer MV, Ziobro JM, et al. Variation in seizure risk increases from antiseizure medication withdrawal among patients with well‐controlled epilepsy: A pooled analysis. Epilepsia Open. 2024;9(1):333-344. doi:10.1002/epi4.12880
BibTeX
@article{Terman2024,
author = {Terman, Samuel W and Slinger, Geertruida and Koek, Adriana and Skvarce, Jeremy and Springer, Mellanie V and Ziobro, Julie M and Burke, James F and Otte, Willem M and Thijs, Roland D and Lossius, Morten I and Marson, Anthony G and Bonnett, Laura J and Braun, Kees P J},
title = {Variation in seizure risk increases from antiseizure medication withdrawal among patients with well‐controlled epilepsy: A pooled analysis},
journal = {Epilepsia Open},
year = {2024},
volume = {9},
number = {1},
pages = {333--344},
doi = {10.1002/epi4.12880}
}
EUVIMED